Literature DB >> 378673

Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide.

C Sonnhag, E Karlsson.   

Abstract

Ten patients with persistent ventricular arrhythmia were studied in a comparison of the antiarrhythmic efficacy of N-acetylprocainamide (NAPA) and procainamide (PA). Each patient performed three exercise tests for 40 min., on different days, with submaximal and fixed work loads. During the first exercise test no drug was administered. During the following two tests PA and NAPA, respectively, were administered by intravenous infusion. The electrocardiogram was continously recorded and was analyzed minute by minute. Blood samples for determination of plasma drug concentration were frequently collected. Exercise alone did not significantly change the incidence of arrhythmia. Both PA and NAPA showed a similar and significant antiarrhythmic effect. A blood pressure fall was seen in two patients after administration of each drug. No other adverse reaction was observed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378673     DOI: 10.1007/bf00558433

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Pharmacokinetics in man of the N-acetylated metabolite of procainamide.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  J Pharmacokinet Biopharm       Date:  1975-08

2.  Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

3.  Hemodynamic changes following procaine amide administered intravenously.

Authors:  R L McCLENDON; W R HANSEN; J M KINSMAN
Journal:  Am J Med Sci       Date:  1951-10       Impact factor: 2.378

4.  Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.

Authors:  W K Lee; J M Strong; R F Kehoe; J S Dutcher; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

5.  N-acetylprocainamide: an active metabolite of procainamide.

Authors:  D E Drayer; M M Reidenberg; R W Sevy
Journal:  Proc Soc Exp Biol Med       Date:  1974-06

6.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

7.  Polymorphic acetylation procainamide in man.

Authors:  M M Reidenberg; D E Drayer; M Levy; H Warner
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

8.  Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions.

Authors:  A J Atkinson; W K Lee; M L Quinn; W Kushner; M J Nevin; J M Strong
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

9.  Effects of long-term treatment with procaine amide. A prospective study with special regard to ANF and SLE in fast and slow acetylators.

Authors:  N C Henningsen; A Cederberg; A Hanson; B W Johansson
Journal:  Acta Med Scand       Date:  1975-12

10.  Comparative evaluation of intravenous phenytoin, procainamide and practolol in the acute treatment of ventricular arrhythmias.

Authors:  E Karlsson; A Kinman; C Sonnhag
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

View more
  4 in total

1.  Efficacy and tolerance of tocainide during acute and long-term treatment of chronic ventricular arrhythmias.

Authors:  C Sonnhag
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

Review 2.  Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.

Authors:  D W Harron; R N Brogden
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

4.  Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.

Authors:  P Ylitalo; R Ruosteenoja; O Leskinen; T Metsä-Ketelä
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.